LianBio ADR Executives

LIANDelisted Stock  USD 2.18  0.05  2.24%   
LianBio ADR employs about 163 people. The company is managed by 11 executives with a total tenure of roughly 381 years, averaging almost 34.0 years of service per executive, having 14.82 employees per reported executive. Analysis of LianBio ADR's management performance can provide insight into the firm performance.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

LianBio ADR Management Team Effectiveness

The company has return on total asset (ROA) of (0.2167) % which means that it has lost $0.2167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3242) %, meaning that it created substantial loss on money invested by shareholders. LianBio ADR's management efficiency ratios could be used to measure how well LianBio ADR manages its routine affairs as well as how well it operates its assets and liabilities.

LianBio ADR Workforce Comparison

LianBio ADR is rated fourth overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,515. LianBio ADR retains roughly 163 in number of employees claiming about 11% of equities under Health Care industry.

LianBio ADR Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific LianBio ADR insiders, such as employees or executives, is commonly permitted as long as it does not rely on LianBio ADR's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, LianBio ADR insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

LianBio ADR Notable Stakeholders

A LianBio ADR stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as LianBio ADR often face trade-offs trying to please all of them. LianBio ADR's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting LianBio ADR's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ehong GuVP CFOProfile
Adam StoneInterim DirectorProfile
Jiang QianChina MangProfile
Konstantin PoukalovFounder ChairmanProfile
Ji ChenSenior CounselProfile
Debra MDPres OfficerProfile
Levvy EngSenior DevelopmentProfile
Yizhe WangCEO DirectorProfile
Yi MBACFO TreasurerProfile
Michael MDChief AdvisorProfile
Brianne JahnChief OfficerProfile

About LianBio ADR Management Performance

The success or failure of an entity such as LianBio ADR often depends on how effective the management is. LianBio ADR management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of LianBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the LianBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey. Lianbio ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.

LianBio ADR Workforce Analysis

Traditionally, organizations such as LianBio ADR use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare LianBio ADR within its industry.

LianBio ADR Manpower Efficiency

Return on LianBio ADR Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee539.8K
Net Loss Per Executive8M
Working Capital Per Employee1.8M
Working Capital Per Executive26.3M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in LianBio Stock

If you are still planning to invest in LianBio ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LianBio ADR's history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like